Christina Aquilante
Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacogenetics | 28 | 2024 | 149 | 6.430 |
Why?
| Pharmacogenomic Testing | 13 | 2022 | 53 | 4.410 |
Why?
| Thiazolidinediones | 8 | 2016 | 142 | 2.800 |
Why?
| Aryl Hydrocarbon Hydroxylases | 10 | 2014 | 41 | 2.480 |
Why?
| Heart Transplantation | 8 | 2021 | 667 | 2.280 |
Why?
| Polymorphism, Genetic | 17 | 2019 | 612 | 2.240 |
Why?
| Precision Medicine | 9 | 2024 | 338 | 1.650 |
Why?
| Polymorphism, Single Nucleotide | 10 | 2021 | 1892 | 1.550 |
Why?
| Hypoglycemic Agents | 11 | 2020 | 1008 | 1.500 |
Why?
| Health Personnel | 4 | 2021 | 574 | 1.470 |
Why?
| Cytochrome P-450 CYP2C19 | 6 | 2024 | 24 | 1.440 |
Why?
| Decision Support Systems, Clinical | 2 | 2024 | 176 | 1.340 |
Why?
| Transplant Recipients | 5 | 2021 | 140 | 1.290 |
Why?
| Blood Pressure | 8 | 2020 | 1530 | 1.220 |
Why?
| Organ Transplantation | 2 | 2020 | 159 | 1.180 |
Why?
| Metabolic Syndrome | 4 | 2016 | 323 | 1.140 |
Why?
| Cytochrome P-450 CYP2D6 | 4 | 2022 | 24 | 1.080 |
Why?
| Graft Rejection | 2 | 2021 | 516 | 1.020 |
Why?
| Pharmacists | 3 | 2022 | 235 | 0.980 |
Why?
| Genotype | 17 | 2024 | 1773 | 0.880 |
Why?
| Cytochrome P-450 CYP3A | 6 | 2016 | 62 | 0.810 |
Why?
| Gemfibrozil | 2 | 2013 | 10 | 0.800 |
Why?
| Adiponectin | 2 | 2016 | 213 | 0.780 |
Why?
| Sulfonylurea Compounds | 3 | 2018 | 44 | 0.770 |
Why?
| Leukopenia | 1 | 2021 | 27 | 0.770 |
Why?
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.760 |
Why?
| Hypolipidemic Agents | 2 | 2013 | 87 | 0.750 |
Why?
| Mycophenolic Acid | 1 | 2021 | 77 | 0.730 |
Why?
| Hypertension | 3 | 2020 | 1059 | 0.720 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2024 | 400 | 0.720 |
Why?
| Desogestrel | 5 | 2021 | 40 | 0.720 |
Why?
| Organic Anion Transporters | 2 | 2011 | 15 | 0.710 |
Why?
| Biological Specimen Banks | 2 | 2024 | 94 | 0.710 |
Why?
| Adult | 41 | 2022 | 30542 | 0.680 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 372 | 0.680 |
Why?
| Middle Aged | 38 | 2021 | 26747 | 0.660 |
Why?
| Humans | 74 | 2024 | 114709 | 0.650 |
Why?
| Prescription Drugs | 2 | 2020 | 116 | 0.640 |
Why?
| Cytochrome P-450 CYP2C8 | 7 | 2014 | 15 | 0.630 |
Why?
| Cardiologists | 1 | 2018 | 40 | 0.630 |
Why?
| Physicians | 3 | 2021 | 772 | 0.610 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2021 | 43 | 0.600 |
Why?
| Female | 50 | 2021 | 59483 | 0.590 |
Why?
| Male | 46 | 2021 | 55554 | 0.590 |
Why?
| HIV Protease Inhibitors | 4 | 2016 | 64 | 0.580 |
Why?
| Academic Medical Centers | 1 | 2020 | 413 | 0.570 |
Why?
| Ritonavir | 4 | 2012 | 71 | 0.560 |
Why?
| Heart Failure | 4 | 2017 | 1952 | 0.550 |
Why?
| Polypharmacy | 1 | 2017 | 74 | 0.540 |
Why?
| Warfarin | 3 | 2008 | 135 | 0.540 |
Why?
| Attitude of Health Personnel | 2 | 2020 | 976 | 0.530 |
Why?
| Lectins | 1 | 2016 | 43 | 0.520 |
Why?
| Antiviral Agents | 1 | 2021 | 646 | 0.510 |
Why?
| Nonprescription Drugs | 1 | 2016 | 68 | 0.510 |
Why?
| Tacrolimus | 1 | 2016 | 134 | 0.500 |
Why?
| Medicare | 1 | 2020 | 665 | 0.490 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2006 | 108 | 0.480 |
Why?
| Contraceptive Agents, Female | 3 | 2020 | 64 | 0.470 |
Why?
| Death, Sudden, Cardiac | 3 | 2021 | 160 | 0.470 |
Why?
| Pediatrics | 2 | 2021 | 983 | 0.460 |
Why?
| Blood Pressure Determination | 1 | 2014 | 122 | 0.440 |
Why?
| Arrhythmias, Cardiac | 3 | 2021 | 278 | 0.440 |
Why?
| Chemokine CXCL5 | 3 | 2012 | 12 | 0.430 |
Why?
| Heptanoic Acids | 1 | 2013 | 60 | 0.420 |
Why?
| Pyrazines | 1 | 2013 | 71 | 0.410 |
Why?
| Diabetes Mellitus, Type 2 | 5 | 2020 | 2096 | 0.410 |
Why?
| Cross-Sectional Studies | 8 | 2020 | 4406 | 0.400 |
Why?
| Resistin | 2 | 2010 | 12 | 0.400 |
Why?
| Pravastatin | 1 | 2011 | 28 | 0.390 |
Why?
| Pyrroles | 1 | 2013 | 183 | 0.390 |
Why?
| Pharmaceutical Preparations | 3 | 2009 | 168 | 0.390 |
Why?
| Triazoles | 1 | 2013 | 130 | 0.390 |
Why?
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 1183 | 0.390 |
Why?
| Dobutamine | 3 | 2008 | 33 | 0.380 |
Why?
| Retrospective Studies | 12 | 2021 | 12511 | 0.370 |
Why?
| Aged | 17 | 2021 | 19078 | 0.350 |
Why?
| Managed Care Programs | 2 | 2022 | 133 | 0.350 |
Why?
| Antidepressive Agents | 2 | 2022 | 194 | 0.350 |
Why?
| Mixed Function Oxygenases | 2 | 2008 | 36 | 0.340 |
Why?
| DNA | 1 | 2016 | 1351 | 0.340 |
Why?
| Drug Interactions | 5 | 2017 | 340 | 0.330 |
Why?
| Young Adult | 13 | 2021 | 10461 | 0.320 |
Why?
| Chromatography, Liquid | 1 | 2010 | 348 | 0.320 |
Why?
| Polymerase Chain Reaction | 3 | 2006 | 994 | 0.320 |
Why?
| Sulfonamides | 1 | 2011 | 445 | 0.310 |
Why?
| Cytokines | 1 | 2016 | 1843 | 0.310 |
Why?
| Drug Prescriptions | 4 | 2021 | 239 | 0.310 |
Why?
| Health | 1 | 2008 | 74 | 0.300 |
Why?
| Time Factors | 8 | 2020 | 6122 | 0.300 |
Why?
| Blood Glucose | 3 | 2016 | 1821 | 0.300 |
Why?
| Chemokine CCL2 | 1 | 2008 | 105 | 0.300 |
Why?
| Heart Rate | 3 | 2008 | 704 | 0.290 |
Why?
| Drug Implants | 4 | 2021 | 70 | 0.290 |
Why?
| Mass Spectrometry | 1 | 2010 | 633 | 0.290 |
Why?
| Immunosuppressive Agents | 4 | 2021 | 647 | 0.290 |
Why?
| Receptors, Adrenergic, beta | 1 | 2008 | 124 | 0.280 |
Why?
| Matrix Metalloproteinase 8 | 1 | 2006 | 8 | 0.280 |
Why?
| Haplotypes | 5 | 2013 | 453 | 0.280 |
Why?
| Electronic Health Records | 3 | 2024 | 801 | 0.280 |
Why?
| Sequence Analysis, DNA | 4 | 2012 | 728 | 0.280 |
Why?
| Vitamin K Epoxide Reductases | 3 | 2020 | 11 | 0.260 |
Why?
| Metoprolol | 1 | 2006 | 37 | 0.260 |
Why?
| Clinical Laboratory Techniques | 1 | 2006 | 87 | 0.260 |
Why?
| Blood Coagulation Factors | 1 | 2006 | 44 | 0.260 |
Why?
| Autonomic Nervous System | 1 | 2006 | 66 | 0.260 |
Why?
| Models, Biological | 1 | 2013 | 1630 | 0.260 |
Why?
| Prospective Studies | 6 | 2020 | 6215 | 0.250 |
Why?
| Administration, Oral | 4 | 2016 | 731 | 0.250 |
Why?
| Anticoagulants | 2 | 2008 | 547 | 0.250 |
Why?
| Clinical Protocols | 2 | 2017 | 232 | 0.250 |
Why?
| Echocardiography | 1 | 2008 | 554 | 0.250 |
Why?
| Cross-Over Studies | 3 | 2013 | 440 | 0.250 |
Why?
| Genetic Variation | 3 | 2019 | 876 | 0.240 |
Why?
| Echocardiography, Stress | 1 | 2004 | 20 | 0.240 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 65 | 0.230 |
Why?
| Cohort Studies | 7 | 2021 | 4899 | 0.230 |
Why?
| Carrier Proteins | 1 | 2008 | 696 | 0.230 |
Why?
| Adrenergic beta-Antagonists | 1 | 2006 | 287 | 0.230 |
Why?
| Metformin | 1 | 2007 | 277 | 0.220 |
Why?
| Biotransformation | 2 | 2013 | 49 | 0.220 |
Why?
| Alleles | 6 | 2012 | 791 | 0.220 |
Why?
| Cytochrome P-450 CYP2C9 | 4 | 2019 | 17 | 0.220 |
Why?
| Waist Circumference | 2 | 2016 | 122 | 0.210 |
Why?
| Gene Frequency | 4 | 2013 | 481 | 0.210 |
Why?
| Follow-Up Studies | 4 | 2021 | 4420 | 0.200 |
Why?
| Clinical Trials as Topic | 1 | 2006 | 934 | 0.200 |
Why?
| Antimalarials | 2 | 2013 | 24 | 0.200 |
Why?
| Drug Dosage Calculations | 1 | 2020 | 21 | 0.180 |
Why?
| Calcineurin Inhibitors | 1 | 2021 | 58 | 0.180 |
Why?
| Pharmacogenomic Variants | 2 | 2021 | 33 | 0.180 |
Why?
| Antibiotics, Antineoplastic | 1 | 2021 | 109 | 0.180 |
Why?
| Egypt | 1 | 2020 | 10 | 0.180 |
Why?
| Aged, 80 and over | 4 | 2017 | 6346 | 0.180 |
Why?
| Cytomegalovirus | 1 | 2021 | 144 | 0.180 |
Why?
| Cardiovascular Diseases | 3 | 2024 | 1727 | 0.180 |
Why?
| Atazanavir Sulfate | 3 | 2016 | 41 | 0.180 |
Why?
| Area Under Curve | 2 | 2013 | 275 | 0.170 |
Why?
| Colorado | 3 | 2024 | 4085 | 0.170 |
Why?
| No-Show Patients | 1 | 2019 | 1 | 0.170 |
Why?
| Menstruation Disturbances | 1 | 2019 | 12 | 0.170 |
Why?
| Hemodynamics | 1 | 2004 | 1013 | 0.170 |
Why?
| United States | 8 | 2021 | 12175 | 0.170 |
Why?
| Smoking | 1 | 2006 | 1384 | 0.170 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 61 | 0.170 |
Why?
| Lipids | 2 | 2016 | 582 | 0.170 |
Why?
| Brain Chemistry | 1 | 2000 | 116 | 0.170 |
Why?
| Cytochrome P450 Family 3 | 1 | 2019 | 2 | 0.170 |
Why?
| Oligopeptides | 2 | 2012 | 234 | 0.160 |
Why?
| Body Weight | 2 | 2016 | 869 | 0.160 |
Why?
| Double-Blind Method | 2 | 2016 | 1662 | 0.160 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 299 | 0.160 |
Why?
| Morphine | 1 | 2000 | 122 | 0.160 |
Why?
| Patients | 1 | 2020 | 162 | 0.160 |
Why?
| Body Mass Index | 3 | 2019 | 1958 | 0.160 |
Why?
| Dose-Response Relationship, Drug | 3 | 2016 | 1846 | 0.150 |
Why?
| Child Health Services | 1 | 2020 | 177 | 0.150 |
Why?
| Bariatric Surgery | 1 | 2021 | 161 | 0.150 |
Why?
| Sitagliptin Phosphate | 2 | 2021 | 30 | 0.150 |
Why?
| Progesterone | 1 | 2019 | 232 | 0.150 |
Why?
| Ventricular Dysfunction | 1 | 2018 | 16 | 0.150 |
Why?
| Psychiatry | 1 | 2020 | 154 | 0.150 |
Why?
| Pyridines | 2 | 2012 | 425 | 0.140 |
Why?
| Apyrase | 1 | 2017 | 14 | 0.140 |
Why?
| Circadian Rhythm | 1 | 2020 | 355 | 0.140 |
Why?
| Depression | 2 | 2022 | 1133 | 0.140 |
Why?
| Organophosphonates | 2 | 2008 | 91 | 0.140 |
Why?
| Healthy Volunteers | 2 | 2019 | 197 | 0.140 |
Why?
| Anti-HIV Agents | 2 | 2016 | 666 | 0.140 |
Why?
| Chronic Disease | 2 | 2017 | 1590 | 0.140 |
Why?
| DNA Primers | 3 | 2006 | 514 | 0.140 |
Why?
| Pyrophosphatases | 1 | 2016 | 22 | 0.140 |
Why?
| Treatment Outcome | 6 | 2021 | 9089 | 0.130 |
Why?
| Cardiology | 1 | 2018 | 259 | 0.130 |
Why?
| GPI-Linked Proteins | 1 | 2016 | 54 | 0.130 |
Why?
| Patient Care | 1 | 2016 | 103 | 0.130 |
Why?
| Adenine | 2 | 2008 | 219 | 0.130 |
Why?
| HIV Infections | 4 | 2016 | 2469 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 271 | 0.130 |
Why?
| Ribavirin | 1 | 2016 | 89 | 0.130 |
Why?
| Students, Pharmacy | 1 | 2016 | 98 | 0.130 |
Why?
| Metabolic Clearance Rate | 2 | 2013 | 102 | 0.120 |
Why?
| Delivery of Health Care | 1 | 2022 | 833 | 0.120 |
Why?
| Therapeutics | 1 | 2015 | 12 | 0.120 |
Why?
| Education, Pharmacy | 1 | 2016 | 125 | 0.120 |
Why?
| beta-Cyclodextrins | 1 | 2015 | 28 | 0.120 |
Why?
| Voriconazole | 1 | 2015 | 24 | 0.120 |
Why?
| Patient Education as Topic | 1 | 2019 | 679 | 0.120 |
Why?
| Surgical Procedures, Operative | 1 | 2017 | 206 | 0.120 |
Why?
| Renal Replacement Therapy | 1 | 2015 | 66 | 0.120 |
Why?
| Adolescent | 6 | 2021 | 17806 | 0.120 |
Why?
| Antigens, CD | 1 | 2017 | 443 | 0.120 |
Why?
| Diltiazem | 1 | 2014 | 23 | 0.120 |
Why?
| Antifungal Agents | 1 | 2015 | 128 | 0.110 |
Why?
| Reoperation | 1 | 2016 | 514 | 0.110 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 2013 | 18 | 0.110 |
Why?
| Kidney Transplantation | 1 | 2019 | 541 | 0.110 |
Why?
| Cardiomyopathies | 1 | 2017 | 298 | 0.110 |
Why?
| Venous Thromboembolism | 1 | 2017 | 231 | 0.110 |
Why?
| Sirolimus | 1 | 2014 | 181 | 0.110 |
Why?
| Half-Life | 1 | 2013 | 141 | 0.110 |
Why?
| Liver Transplantation | 1 | 2019 | 706 | 0.100 |
Why?
| Practice Patterns, Physicians' | 1 | 2020 | 1177 | 0.100 |
Why?
| Medication Adherence | 1 | 2017 | 537 | 0.100 |
Why?
| Tissue Distribution | 2 | 2014 | 285 | 0.100 |
Why?
| Darunavir | 1 | 2011 | 17 | 0.100 |
Why?
| Lung Transplantation | 1 | 2014 | 246 | 0.100 |
Why?
| Self Care | 1 | 2014 | 350 | 0.100 |
Why?
| Genetic Association Studies | 1 | 2013 | 344 | 0.090 |
Why?
| Prevalence | 1 | 2017 | 2249 | 0.090 |
Why?
| Insulin Resistance | 2 | 2010 | 1072 | 0.090 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 218 | 0.090 |
Why?
| Patient Discharge | 1 | 2016 | 768 | 0.090 |
Why?
| Reverse Transcriptase Inhibitors | 2 | 2008 | 82 | 0.090 |
Why?
| Phenotype | 2 | 2016 | 2811 | 0.090 |
Why?
| Cholesterol | 1 | 2011 | 368 | 0.090 |
Why?
| Longitudinal Studies | 1 | 2016 | 2381 | 0.080 |
Why?
| Kidney Failure, Chronic | 1 | 2015 | 487 | 0.080 |
Why?
| Triglycerides | 1 | 2011 | 470 | 0.080 |
Why?
| Leukocytes | 2 | 2012 | 277 | 0.080 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2010 | 123 | 0.080 |
Why?
| Lipoproteins | 1 | 2010 | 160 | 0.080 |
Why?
| Risk Assessment | 3 | 2020 | 2973 | 0.080 |
Why?
| Surveys and Questionnaires | 1 | 2020 | 4621 | 0.080 |
Why?
| Databases, Factual | 3 | 2021 | 1126 | 0.080 |
Why?
| Incidence | 2 | 2020 | 2312 | 0.070 |
Why?
| Lung Diseases | 1 | 2014 | 696 | 0.070 |
Why?
| Weight Gain | 2 | 2021 | 451 | 0.070 |
Why?
| Drug Delivery Systems | 1 | 2010 | 296 | 0.070 |
Why?
| Biomarkers | 3 | 2014 | 3414 | 0.070 |
Why?
| Reproducibility of Results | 1 | 2014 | 2762 | 0.070 |
Why?
| Pyrimidinones | 1 | 2007 | 88 | 0.070 |
Why?
| Indinavir | 1 | 2006 | 6 | 0.070 |
Why?
| Linear Models | 2 | 2019 | 770 | 0.070 |
Why?
| Cost-Benefit Analysis | 2 | 2012 | 545 | 0.070 |
Why?
| Genetic Techniques | 1 | 2006 | 58 | 0.070 |
Why?
| Prognosis | 2 | 2014 | 3334 | 0.070 |
Why?
| Lamivudine | 1 | 2006 | 59 | 0.070 |
Why?
| Factor X | 1 | 2006 | 24 | 0.070 |
Why?
| Zidovudine | 1 | 2006 | 77 | 0.070 |
Why?
| Prothrombin | 1 | 2006 | 22 | 0.070 |
Why?
| Oxidation-Reduction | 1 | 2009 | 927 | 0.070 |
Why?
| Factor VII | 1 | 2006 | 26 | 0.070 |
Why?
| International Normalized Ratio | 1 | 2006 | 45 | 0.070 |
Why?
| Chemokines, CXC | 1 | 2006 | 58 | 0.070 |
Why?
| Drug Utilization | 1 | 2007 | 167 | 0.070 |
Why?
| C-Reactive Protein | 1 | 2008 | 362 | 0.060 |
Why?
| Base Sequence | 2 | 2006 | 2118 | 0.060 |
Why?
| Regression Analysis | 1 | 2008 | 946 | 0.060 |
Why?
| Delayed-Action Preparations | 1 | 2006 | 159 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2014 | 2321 | 0.060 |
Why?
| Health Care Surveys | 1 | 2007 | 539 | 0.060 |
Why?
| Risk Factors | 3 | 2020 | 8625 | 0.060 |
Why?
| Mathematical Computing | 1 | 2004 | 12 | 0.060 |
Why?
| Gene Expression | 1 | 2009 | 1420 | 0.060 |
Why?
| Kidney | 2 | 2008 | 1184 | 0.060 |
Why?
| Drug Labeling | 1 | 2004 | 42 | 0.060 |
Why?
| Infusions, Intravenous | 1 | 2004 | 372 | 0.050 |
Why?
| Laboratories | 1 | 2004 | 95 | 0.050 |
Why?
| Multidrug Resistance-Associated Proteins | 3 | 2008 | 35 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2007 | 1078 | 0.050 |
Why?
| Reference Values | 1 | 2004 | 741 | 0.050 |
Why?
| Linagliptin | 1 | 2021 | 4 | 0.050 |
Why?
| Adamantane | 1 | 2021 | 16 | 0.050 |
Why?
| Administrative Claims, Healthcare | 1 | 2021 | 21 | 0.050 |
Why?
| Dipeptides | 1 | 2021 | 48 | 0.050 |
Why?
| Electrocardiography | 1 | 2004 | 562 | 0.050 |
Why?
| Electronic Prescribing | 1 | 2021 | 3 | 0.050 |
Why?
| Uterine Hemorrhage | 1 | 2021 | 35 | 0.050 |
Why?
| Animals | 3 | 2008 | 31761 | 0.040 |
Why?
| Protective Factors | 1 | 2020 | 87 | 0.040 |
Why?
| Drug Tolerance | 1 | 2000 | 79 | 0.040 |
Why?
| Costs and Cost Analysis | 1 | 2020 | 195 | 0.040 |
Why?
| Treatment Failure | 1 | 2020 | 332 | 0.040 |
Why?
| Genomics | 1 | 2024 | 639 | 0.040 |
Why?
| Homozygote | 2 | 2012 | 187 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 815 | 0.040 |
Why?
| Diabetes Mellitus | 1 | 2006 | 904 | 0.040 |
Why?
| Genetic Testing | 1 | 2021 | 379 | 0.040 |
Why?
| Antineoplastic Agents | 1 | 2009 | 1895 | 0.040 |
Why?
| Attitude | 1 | 2020 | 229 | 0.040 |
Why?
| Liver | 1 | 2006 | 1631 | 0.040 |
Why?
| Proportional Hazards Models | 1 | 2021 | 1080 | 0.040 |
Why?
| Feasibility Studies | 1 | 2021 | 737 | 0.040 |
Why?
| Glipizide | 1 | 2018 | 6 | 0.040 |
Why?
| Organic Anion Transport Protein 1 | 2 | 2008 | 6 | 0.040 |
Why?
| Social Class | 1 | 2019 | 204 | 0.040 |
Why?
| Glyburide | 1 | 2018 | 35 | 0.040 |
Why?
| Dexamethasone | 1 | 2000 | 317 | 0.040 |
Why?
| Self-Management | 1 | 2019 | 126 | 0.040 |
Why?
| Self Report | 1 | 2021 | 695 | 0.040 |
Why?
| Anesthetics | 1 | 2017 | 54 | 0.030 |
Why?
| Membrane Transport Proteins | 2 | 2008 | 138 | 0.030 |
Why?
| Tenofovir | 2 | 2008 | 204 | 0.030 |
Why?
| Peru | 1 | 2016 | 54 | 0.030 |
Why?
| Perioperative Care | 1 | 2017 | 126 | 0.030 |
Why?
| Cause of Death | 1 | 2018 | 362 | 0.030 |
Why?
| Pharmaceutical Services | 1 | 2016 | 78 | 0.030 |
Why?
| Medicaid | 1 | 2020 | 407 | 0.030 |
Why?
| Diabetic Angiopathies | 1 | 2018 | 244 | 0.030 |
Why?
| Indians, North American | 1 | 2021 | 570 | 0.030 |
Why?
| South Africa | 1 | 2016 | 161 | 0.030 |
Why?
| Alternative Splicing | 1 | 2017 | 188 | 0.030 |
Why?
| Preoperative Care | 1 | 2017 | 317 | 0.030 |
Why?
| HEK293 Cells | 1 | 2017 | 593 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2000 | 2209 | 0.030 |
Why?
| Hepatitis C, Chronic | 1 | 2016 | 151 | 0.030 |
Why?
| Receptors, Steroid | 1 | 2014 | 47 | 0.030 |
Why?
| Everolimus | 1 | 2014 | 61 | 0.030 |
Why?
| Hypoglycemia | 1 | 2018 | 386 | 0.030 |
Why?
| Demography | 1 | 2014 | 262 | 0.030 |
Why?
| Mental Disorders | 1 | 2020 | 889 | 0.030 |
Why?
| Age Factors | 1 | 2019 | 2889 | 0.030 |
Why?
| Vasodilator Agents | 1 | 2014 | 303 | 0.030 |
Why?
| Heterozygote | 1 | 2012 | 251 | 0.020 |
Why?
| Rats | 1 | 2000 | 4943 | 0.020 |
Why?
| Genetic Loci | 1 | 2012 | 263 | 0.020 |
Why?
| Insulin | 1 | 2019 | 2079 | 0.020 |
Why?
| Critical Illness | 1 | 2015 | 643 | 0.020 |
Why?
| Algorithms | 2 | 2008 | 1468 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2017 | 2099 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 1435 | 0.020 |
Why?
| Body Composition | 1 | 2012 | 592 | 0.020 |
Why?
| Plasma | 1 | 2009 | 210 | 0.020 |
Why?
| Lopinavir | 1 | 2007 | 29 | 0.020 |
Why?
| PubMed | 1 | 2006 | 10 | 0.020 |
Why?
| Ribosomal Proteins | 1 | 2006 | 70 | 0.020 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 256 | 0.020 |
Why?
| Pharmacology | 1 | 2005 | 8 | 0.020 |
Why?
| RNA, Messenger | 1 | 2012 | 2557 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2009 | 2791 | 0.010 |
Why?
| Likelihood Functions | 1 | 2005 | 126 | 0.010 |
Why?
| Mitochondrial Proteins | 1 | 2006 | 219 | 0.010 |
Why?
| Cardiotonic Agents | 1 | 2005 | 119 | 0.010 |
Why?
| Hemorrhage | 1 | 2008 | 618 | 0.010 |
Why?
| Genome | 1 | 2006 | 272 | 0.010 |
Why?
| Chromosome Mapping | 1 | 2005 | 489 | 0.010 |
Why?
| Drug Therapy, Combination | 1 | 2006 | 954 | 0.010 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2006 | 333 | 0.010 |
Why?
| Predictive Value of Tests | 1 | 2008 | 1795 | 0.010 |
Why?
| Models, Genetic | 1 | 2005 | 565 | 0.010 |
Why?
| Child | 1 | 2020 | 18348 | 0.010 |
Why?
| Pilot Projects | 1 | 2006 | 1370 | 0.010 |
Why?
| Computer Simulation | 1 | 2005 | 878 | 0.010 |
Why?
| Case-Control Studies | 1 | 2007 | 3004 | 0.010 |
Why?
| Inflammation | 1 | 2006 | 2481 | 0.010 |
Why?
|
|
Aquilante's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|